Donald Notman

Director of Finance/CFO at OCULAR THERAPEUTIX, INC.

Net worth: 820 495 $ as of 2024-04-29

64 year

34 connections

Health Technology

Consumer Services

Finance

Active connections

Name	Gender	Age	Linked companies	Collaboration
Jeffrey S. Heier	M	63	OCULAR THERAPEUTIX, INC.	9 years
Charles M. Warden	M	55	OCULAR THERAPEUTIX, INC.	16 years
Scott Corning	M	-	OCULAR THERAPEUTIX, INC.	14 years
Richard Lindstrom	M	76	OCULAR THERAPEUTIX, INC.	12 years
Merilee Raines	F	68	OCULAR THERAPEUTIX, INC.	3 years
Leslie Williams	F	64	OCULAR THERAPEUTIX, INC.	5 years
Seung Suh Hong	M	66	OCULAR THERAPEUTIX, INC.	5 years
Adrienne Graves	M	69	OCULAR THERAPEUTIX, INC.	1 years
Tracy Smith	F	-	OCULAR THERAPEUTIX, INC.	4 years
Rabia Ozden	M	56	OCULAR THERAPEUTIX, INC.	3 years
Pravin Dugel	M	60	OCULAR THERAPEUTIX, INC.	-
Philip Strassburger	M	64	OCULAR THERAPEUTIX, INC.	4 years
Peter K. Kaiser	M	-	OCULAR THERAPEUTIX, INC.	-
Pauline Jen Ryan	F	-	OCULAR THERAPEUTIX, INC.	-
Christopher White	M	62	OCULAR THERAPEUTIX, INC.	5 years
Peter Jarrett	M	-	OCULAR THERAPEUTIX, INC.	17 years
Karen-Leigh Edwards	M	-	OCULAR THERAPEUTIX, INC.	3 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Amarpreet S. Sawhney	M	57	OCULAR THERAPEUTIX, INC.	13 years
Antony Mattessich	M	57	OCULAR THERAPEUTIX, INC.	7 years
Jim O'Shea	M	74	OCULAR THERAPEUTIX, INC.	4 years
Bruce Peacock	M	72	OCULAR THERAPEUTIX, INC.	8 years
Joseph Zakrzewski	M	60	Thrasos Therapeutics, Inc. Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada.	-
George Migausky	M	69	OCULAR THERAPEUTIX, INC.	-
Patricia Kitchen	F	46	OCULAR THERAPEUTIX, INC.	2 years
Chad Brines	M	-	OCULAR THERAPEUTIX, INC.	4 years
Jonathan M. Sparks	M	-	OCULAR THERAPEUTIX, INC.	-
Nicole Carta	F	-	OCULAR THERAPEUTIX, INC.	-
Michael H. Goldstein	M	57	OCULAR THERAPEUTIX, INC.	-
Kevin Hanley	M	62	OCULAR THERAPEUTIX, INC.	2 years
Naymisha Patel	F	-	OCULAR THERAPEUTIX, INC.	-
Daniel M. Bollag	M	63	OCULAR THERAPEUTIX, INC.	2 years
Gaétan Gravel	M	-	Thrasos Therapeutics, Inc. Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada.	-
Jaswinder S. Chadha	M	56	OCULAR THERAPEUTIX, INC.	6 years
Amar Sawhney	M	-	OCULAR THERAPEUTIX, INC.	2 years

Statistics

Country	Connections	% of total
United States	32	94.12%
Canada	2	5.88%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections